VENLO, The Netherlands, July 9, 2007 (PRIME NEWSWIRE) -- QIAGEN N.V. (NasdaqGS:QGEN - News); (Frankfurt:QIA.F - News), the world’s leading provider of sample and assay technologies for research in life sciences, applied testing and molecular diagnostics, today announced that its subsidiary QIAGEN North American Holdings, Inc. has completed its acquisition of eGene, Inc. in a transaction at $0.65 in cash and 0.0416 common shares of QIAGEN stock per share of eGene common stock. The transaction has been publicly announced on April 12, 2007. The aggregate purchase consideration amounts to approximately $34.0 million and consists of $15.5 million in cash and 1.0 million common shares of QIAGEN stock valued at $17.0 million (based on the average closing prices of QIAGEN common shares on the NASDAQ Global Select Market for the 20 trading days ending on April 12, 2007), as well as the assumption of certain liabilities in the amount of approximately $1.5 million.
